Literature DB >> 25599535

Upregulation of integrin β4 promotes epithelial-mesenchymal transition and is a novel prognostic marker in pancreatic ductal adenocarcinoma.

Y Masugi1, K Yamazaki1, K Emoto1, K Effendi1, H Tsujikawa1, M Kitago2, O Itano2, Y Kitagawa2, M Sakamoto1.   

Abstract

Pancreatic ductal adenocarcinoma (PDA) is a highly aggressive and often lethal malignant tumor. Several studies have shown that epithelial-mesenchymal transition (EMT) is frequently observed in clinical samples of PDA and is related to high metastatic rates and poor outcomes. To identify candidate molecules regulating EMT in PDA, we previously used cDNA microarray analysis and identified integrin β4 (ITGB4) as one of the genes upregulated in high-EMT xenografts derived from PDA patients. The aim of the current study was to clarify the clinicopathological and functional significance of ITGB4 overexpression in PDA. ITGB4 upregulation in high-EMT xenografts was confirmed by immunohistochemistry. Immunohistochemical analyses of 134 surgically resected PDA cases revealed intratumoral heterogeneity with respect to ITGB4 expression and showed that cancer cells undergoing EMT often display strong diffuse ITGB4 expression. High levels of ITGB4 expression were significantly correlated with the hallmarks of EMT (solitary cell infiltration, reduced E-cadherin expression, and increased vimentin expression), with high tumor grade, and with the presence of lymph node metastasis, and showed an independent prognostic effect. Immunocytochemical analyses of PDA cell lines revealed that localization of ITGB4 changed from regions of cell-cell contact to diffuse cytoplasm and cell edges with occasional localization in filopodia during EMT. Knockdown of ITGB4 reduced the migratory and invasive ability of PDA cells. Overexpression of ITGB4 promoted cell scattering and cell motility in combination with downregulation of E-cadherin and upregulation of vimentin expression. In conclusion, we elucidated the prognostic and clinicopathological significance of ITGB4 overexpression in PDA and also the potential role for ITGB4 in the regulation of cancer invasion and EMT.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25599535     DOI: 10.1038/labinvest.2014.166

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  32 in total

1.  Reduced transforming growth factor-beta receptor II expression in hepatocellular carcinoma correlates with intrahepatic metastasis.

Authors:  Takao Mamiya; Ken Yamazaki; Yohei Masugi; Taisuke Mori; Kathryn Effendi; Wenlin Du; Taizo Hibi; Minoru Tanabe; Masakazu Ueda; Tadatoshi Takayama; Michiie Sakamoto
Journal:  Lab Invest       Date:  2010-06-07       Impact factor: 5.662

Review 2.  Epithelial-mesenchymal transitions in development and disease.

Authors:  Jean Paul Thiery; Hervé Acloque; Ruby Y J Huang; M Angela Nieto
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

3.  Epithelial-mesenchymal transition and mesenchymal-epithelial transition via regulation of ZEB-1 and ZEB-2 expression in pancreatic cancer.

Authors:  Hiroshi Kurahara; Sonshin Takao; Kosei Maemura; Yuko Mataki; Taisaku Kuwahata; Koki Maeda; Qiang Ding; Masahiko Sakoda; Satoshi Iino; Sumiya Ishigami; Shinichi Ueno; Hiroyuki Shinchi; Shoji Natsugoe
Journal:  J Surg Oncol       Date:  2011-12-27       Impact factor: 3.454

4.  Prognostic value of alpha 6 beta 4 integrin expression in breast carcinomas is affected by laminin production from tumor cells.

Authors:  E Tagliabue; C Ghirelli; P Squicciarini; P Aiello; M I Colnaghi; S Ménard
Journal:  Clin Cancer Res       Date:  1998-02       Impact factor: 12.531

5.  Expression of the alpha6beta4 integrin provides prognostic information in bladder cancer.

Authors:  H B Grossman; C Lee; J Bromberg; M Liebert
Journal:  Oncol Rep       Date:  2000 Jan-Feb       Impact factor: 3.906

Review 6.  Targeting integrin beta4 for cancer and anti-angiogenic therapy.

Authors:  Filippo G Giancotti
Journal:  Trends Pharmacol Sci       Date:  2007-09-05       Impact factor: 14.819

Review 7.  Biologic therapies for advanced pancreatic cancer.

Authors:  Aiwu Ruth He; Andreas Peter Lindenberg; John Lindsay Marshall
Journal:  Expert Rev Anticancer Ther       Date:  2008-08       Impact factor: 4.512

8.  Hepatocyte growth factor and Met receptor expression in human pancreatic carcinogenesis.

Authors:  T Furukawa; W P Duguid; M Kobari; S Matsuno; M S Tsao
Journal:  Am J Pathol       Date:  1995-10       Impact factor: 4.307

Review 9.  The basics of epithelial-mesenchymal transition.

Authors:  Raghu Kalluri; Robert A Weinberg
Journal:  J Clin Invest       Date:  2009-06       Impact factor: 14.808

10.  The integrin alpha6beta4 functions in carcinoma cell migration on laminin-1 by mediating the formation and stabilization of actin-containing motility structures.

Authors:  I Rabinovitz; A M Mercurio
Journal:  J Cell Biol       Date:  1997-12-29       Impact factor: 10.539

View more
  28 in total

Review 1.  Clinical significance of the integrin α6β4 in human malignancies.

Authors:  Rachel L Stewart; Kathleen L O'Connor
Journal:  Lab Invest       Date:  2015-06-29       Impact factor: 5.662

2.  Analysis of differentially expressed genes, clinical value and biological pathways in prostate cancer.

Authors:  Zhaohui He; Fucai Tang; Zechao Lu; Yucong Huang; Hanqi Lei; Zhibiao Li; Guohua Zeng
Journal:  Am J Transl Res       Date:  2018-05-15       Impact factor: 4.060

3.  Integrin-β4 identifies cancer stem cell-enriched populations of partially mesenchymal carcinoma cells.

Authors:  Brian Bierie; Sarah E Pierce; Cornelia Kroeger; Daniel G Stover; Diwakar R Pattabiraman; Prathapan Thiru; Joana Liu Donaher; Ferenc Reinhardt; Christine L Chaffer; Zuzana Keckesova; Robert A Weinberg
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-07       Impact factor: 11.205

4.  Identification of hub genes and analysis of prognostic values in pancreatic ductal adenocarcinoma by integrated bioinformatics methods.

Authors:  Yi Lu; Chujun Li; Honglei Chen; Weijie Zhong
Journal:  Mol Biol Rep       Date:  2018-09-01       Impact factor: 2.316

5.  High-resolution myogenic lineage mapping by single-cell mass cytometry.

Authors:  Ermelinda Porpiglia; Nikolay Samusik; Andrew Tri Van Ho; Benjamin D Cosgrove; Thach Mai; Kara L Davis; Astraea Jager; Garry P Nolan; Sean C Bendall; Wendy J Fantl; Helen M Blau
Journal:  Nat Cell Biol       Date:  2017-04-17       Impact factor: 28.824

Review 6.  The Desmoplastic Stroma of Pancreatic Cancer: Multilayered Levels of Heterogeneity, Clinical Significance, and Therapeutic Opportunities.

Authors:  Yohei Masugi
Journal:  Cancers (Basel)       Date:  2022-07-05       Impact factor: 6.575

7.  Extracellular matrix gene expression profiling using microfluidics for colorectal carcinoma stratification.

Authors:  Christopher J Hayes; Catriona M Dowling; Susan Dwane; Mary E McCumiskey; Shona M Tormey; B Anne Merrigan; John C Coffey; Patrick A Kiely; Tara M Dalton
Journal:  Biomicrofluidics       Date:  2016-10-31       Impact factor: 2.800

8.  Integrin β4 in EMT: an implication of renal diseases.

Authors:  Qi Wang; Yan Wang; Xiaoyan Huang; Wei Liang; Zibo Xiong; Zuying Xiong
Journal:  Int J Clin Exp Med       Date:  2015-05-15

9.  Integrin β4 promotes cell invasion and epithelial-mesenchymal transition through the modulation of Slug expression in hepatocellular carcinoma.

Authors:  Xiao-Long Li; Lin Liu; Dan-Dan Li; Ya-Ping He; Le-Hang Guo; Li-Ping Sun; Lin-Na Liu; Hui-Xiong Xu; Xiao-Ping Zhang
Journal:  Sci Rep       Date:  2017-01-13       Impact factor: 4.379

10.  PHLPP negatively regulates cell motility through inhibition of Akt activity and integrin expression in pancreatic cancer cells.

Authors:  Alena J Smith; Yang-An Wen; Payton D Stevens; Jingpeng Liu; Chi Wang; Tianyan Gao
Journal:  Oncotarget       Date:  2016-02-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.